Please login to the form below

Not currently logged in
Email:
Password:

New Accounts, July, 2006 - Advertising

The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period April 2006 to June 2006 inclusive

The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period April 2006 to June 2006 inclusive. Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may also be involved with some of the products listed in other ways, or in domestic, overseas or international markets. To submit an entry for New Accounts, email new_accounts@pmlive.com

Actelion Pharmaceuticals

Tracleer

Cardiovascular

Woolley Pau

Alliance Pharmaceuticals

Hydromol

Dermatology

RFA Advertising & Marketing

AstraZeneca

Meronem

Antibiotics

GSW Worldwide

British Medical Journal

Clinical Evidence

N/A

The Foundry

Galen

Calceos

Calcium supplement

Dark Horse

Galen

Miacalcic

Post-menopausal osteoporosis

Dark Horse

Galen

Regurin

Overactive bladder

Woolley Pau

Kogen

Diclomax

Arthritis and pain

Swordfish Advertising

Janssen-Cilag

Multimedia project

Migraine

RFA Advertising and Marketing

Novartis

Diovan/CoDiovan

Cardiovascular

ICC (Lowe Healthcare WW)

Nycomed

New products

N/A

Lowe Azure

Pfizer Consumer Healthcare UK

Media activity

OTC and POM portfolio

Medical Media Services

Pliva

Cystistat

Interstitial cystitis

RFA Advertising & Marketing

Sanofi Pasteur MSD

Childhood vaccines portfolio

Vaccines

Swordfish Advertising

Wyeth

Prevenar

Vaccines

Scholz & Friends Life Science

2nd September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...